Dror Bashan
2021
In 2021, Dror Bashan earned a total compensation of $1.2M as President and Chief Executive Officer at Protalix BioTherapeutics, a 14% decrease compared to previous year.
Compensation breakdown
Option Awards | $82,371 |
---|---|
Salary | $373,817 |
Stock Awards | $585,224 |
Other | $116,287 |
Total | $1,157,699 |
Bashan received $585.2K in stock awards, accounting for 51% of the total pay in 2021.
Bashan also received $82.4K in option awards, $373.8K in salary and $116.3K in other compensation.
Rankings
In 2021, Dror Bashan's compensation ranked 8,259th out of 12,415 executives tracked by ExecPay. In other words, Bashan earned more than 33.5% of executives.
Classification | Ranking | Percentile |
---|---|---|
All | 8,259 out of 12,415 | 34th |
Division Manufacturing | 3,654 out of 5,508 | 34th |
Major group Chemicals And Allied Products | 1,625 out of 2,378 | 32nd |
Industry group Drugs | 1,445 out of 2,099 | 31st |
Industry Biological Products, Except Diagnostic Substances | 321 out of 449 | 29th |
Source: SEC filing on April 29, 2022.
Bashan's colleagues
We found three more compensation records of executives who worked with Dror Bashan at Protalix BioTherapeutics in 2021.
News
Protalix BioTherapeutics CEO Dror Bashan's 2023 pay jumps 83% to $2.7M
April 29, 2024
Protalix BioTherapeutics CEO Dror Bashan's 2022 pay jumps 27% to $1.5M
May 18, 2023
Protalix BioTherapeutics CEO Dror Bashan's 2021 pay slips 14% to $1.2M
April 29, 2022
Protalix BioTherapeutics CEO Moshe Manor's 2019 pay slips 14% to $616K
April 15, 2020